Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1421-1430 of 3416 for cancer

Edit search filters
  1. Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

    Rochester, MN

  2. Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

  3. Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

    Rochester, MN

  4. Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Retifanlimab

    Jacksonville, FL

  5. Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

    Jacksonville, FL

  6. Study to Evaluate Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  7. Risk-Adapted Chemotherapy in Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

    Rochester, MN

  8. A Study to Evaluate Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently- Detectable Minimal Residual Disease

    Eau Claire, WI, Rochester, MN

  9. GB5121 in Adult Subjects With Relapsed/Refractory CNS Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

    Rochester, MN, Jacksonville, FL

.

Mayo Clinic Footer